Day One Announces Preliminary Phase 1 Results for DAY101 in Pediatric Low-Grade Glioma, Receipt of Breakthrough Therapy Designation (BTD) and New Phase 2 Study

This is big news! The ability to inhibit oncogenic BRAF in PLGAs by DAY101 (formerly TAK580) was discovered right here at Dana-Farber by investigators supported by the PLGA Foundation. This therapy would not exist without the vision, determination and persistence of our team of families, donors, basic scientists, clinicians and industry. An amazing example of “Yes, together we can!”

Read more here.